drugset / Trial / NCT00111111

An Evaluation of Etanercept in the Treatment of Subjects With Psoriasis

NCT00111111

Phase 3 Completed Amgen
RandomizedFactorialOpen-labelTreatment

Summary

The purpose of this multicenter, open-label, prospective study is to evaluate the effectiveness and safety of etanercept in the treatment of subjects with psoriasis.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg

Indications